introduction. The first observations of "geant buccal aphtosis" induced by
nicorandil were published in 1996 Nicorandil is a potassium channel activat
or used in the treatment of angina pectoris, which seems to induce specific
buccal ulcerations. The purpose of this study was to analyze the clinicopa
thologic data of patients with aphtosis induced by nicorandil and to study
the prevalence of this side effect.
Patients and methods. We have seen 3 patients who spontaneously consulted,
and 5 patients who were adressed to us after a telephone survey: We have th
en examined 100 consecutive patients treated by nicorandil for at least 1 m
onth, who were hospitalized in 3 departments of cardiology in Strasbourg, a
nd too age -and sex- matched controls who were treated by other antianginal
drugs.
Results. Our 8 patients suffered from large, chronic and painful ulceration
s of a 4-week duration, located on the tongue, the gingiva and the cheeks d
espite various symptomatic treatments. In one case, histopathologic data we
re consistent with an eosinophilic ulcer. Prospective study: among 100 pati
ents treated by nicorandil, 5 had unusual chronic buccal ulcerations, where
as none of the 100 controls had aphtosis (p = 0.03). The confidence interva
l (99 p. 100) of this side effect prevalence was therefore 1 p. too to 14 p
. 100.
Discussion. Nicorandil can induce large and painful buccal ulcerations with
severe dysphagia, weight loss, and depression. Dermatologists should be aw
ared of this particuliar side-effect, since our study showed a high prevale
nce, and because lesions heal rapidly after withdrawal of nicorandil. Why n
icorandil may be associated with mouth ulcers remains unanswered. A past hi
story of aphtae could be a cofactor of this side-effect.